Adrianus Johannes De Langen

机构：The Netherlands Cancer Institute, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital · ORCID：0000-0001-7343-633X

发表论文 129 篇 · 总被引 3714 次 · h-index 26

代表论文

• Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer (2025 · Nature Medicine · 被引 39)
• Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC (2025 · Journal of Thoracic Oncology · 被引 23)
• 1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD (2025 · Journal of Thoracic Oncology · 被引 22)
• Trastuzumab Deruxtecan for ERBB2 -Mutant Metastatic Non–Small Cell Lung Cancer With or Without Brain Metastases (2025 · JAMA Network Open · 被引 16)
• Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer (2025 · The Oncologist · 被引 12)
• Physiologically Based Pharmacokinetic Model of Tyrosine Kinase Inhibitors to Predict Target Site Penetration, with PET ‐Guided Verification (2025 · CPT Pharmacometrics & Systems Pharmacology · 被引 11)